EcoDrugPlus

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSCVAG00000007852
Gene Symbol: PSMB3
3 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSCVAG00000002181
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSCVAG00000006339
Gene Symbol: PSMB5
3 Cross references
223 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSCVAG00000021276
Gene Symbol: PSMB7
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCVAG00000005044
Gene Symbol: PSMB8
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSCVAG00000016888
Gene Symbol: PSMB8A
1 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSCVAG00000009196
Gene Symbol: PSMB9A
1 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSCVAG00000011851
Gene Symbol: PSMC1
3 Cross references
318 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSCVAG00000001766
Gene Symbol: PSMC2
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSCVAG00000010638
Gene Symbol: PSMC3
3 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSCVAG00000009319
Gene Symbol: PSMC4
3 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSCVAG00000020760
Gene Symbol: PSMC5
3 Cross references
229 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).